2018
In March, a new single-tablet formulation of ibrutinib was introduced as an innovation for patients with a one pill, once-a-day dosing regimen. This new formulation was developed with the intention of improving daily adherence, available in four dosing strengths (560, 420, 280, and 140 mg tablets), in addition to the existing 140 mg capsule formulation.
In August, the FDA approved ibrutinib plus rituximab as the first chemotherapy-free treatment for adult patients with Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL).